The Primary Objective is to evaluate the safety and tolerability of the DTRMWXHS-12 capsule
in patients with relapsed/refractory MCL and recommend the dose and dosing method (RP2D) used
in phase II study.
The Secondary Objective is to evaluate the pharmacokinetics (PK) of multiple dose oral
administration of DTRMWXHS-12 capsule in patients with relapsed/refractory MCL.
The Exploratory Objective is to preliminarily evaluate the efficacy of DTRMWXHS-12 capsule in
patients with relapsed/refractory MCL.